Celera Genomics Hires James Peck as Vice President, Product Development.

ROCKVILLE, Md.--(BW Health Wire)--Dec. 8, 1999--

Celera Genomics (NYSE:CRA), a PE Corporation business, announced today that James M. Peck, 36, has joined Celera as vice president, product development. He will report to J. Craig Venter, PhD, president and chief scientific officer, Celera.

In this new position, Peck will play a pivotal role in achieving Celera's mission to become the definitive source of genomic and related agricultural and medical information. He will be responsible for defining Celera's product strategy and for development of the company's state-of-the art research information system tailored to the customers' needs. Peck and his team will initially focus on development of products for Celera's target markets, including the pharmaceutical and agricultural industries.

Peck joins Celera from LEXIS-NEXIS, where he spent the last ten years developing both internal and end-user software applications for LEXIS-NEXIS, a pioneer in on-line research. In his most recent job there as vice-president of electronic publishing, he led the development of lexis.com legal research system targeted at LEXIS' $500 million legal research revenue stream. Peck also held positions at General Motors Corporation in Detroit. Peck received his bachelor's degree in management information systems at the University of Dayton in 1985 and his master's degree in business administration from the Ohio State University in 1989.

Celera's information is available through the Internet on a subscription basis to academic and commercial institutions. Users will have the ability to view, browse, and analyze data in an integrated way, thus accelerating their understanding of a variety of genomes, including the human, Drosophila, and ultimately the mouse and agricultural genomes.

"Jim's extensive experience in innovative development and marketing of large data accessing products make him uniquely qualified to lead Celera's product development efforts. Celera's goal is to become the preeminent genomic and life sciences information portal, and Jim and his team will be integral to achieving this goal," said J. Craig Venter, PhD, Celera's president and chief scientific officer.

"We will focus significant energy understanding how to package Celera's scientific data and provide the most advanced applications for our customers. By making a dramatic impact on a company's research, our goal is to help customers achieve breakthrough productivity," added Peck.

PE Corporation currently comprises two operating groups. Celera Genomics Group, headquartered in Rockville, Maryland, intends to become the definitive source of genomic and related medical information. PE Biosystems Group, headquartered in foster City, California and with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software, and contract related services to the life science industry and research community. Information about the Company, including consolidated financial statements of PE Corporation, is available on the World Wide Web at http://www.pe-corp.com or by phoning 800/762-6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as "believe," "expect," "anticipate," "should," "planned," "estimated," and "potential," among others. These forward-looking statements are based on PE Corporation's current expectations. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics' businesses include but are not limited to (1) early state of operations and uncertainty of operating results;(2) no precedent for Celera Genomics' business plan;(3) uncertainty of sequencing strategy;(4) uncertainty of successful operation of new sequencers and sequencing operations;(5) uncertainty of value of polymorphism data;(6) initial reliance on pharmaceutical industry;(7) high dependence on key employees;(8) uncertain protection of intellectual property and proprietary rights;(9) adverse effect of public disclosure of genomic sequence data;(10) highly competitive business;(11) need to manage rapid growth;(12) uncertainty of success of Year 2000 compliance plan; and (13) other factors that might be described from time to time in PE Corporation's filings with the Securities and Exchange Commission.